 phase clinic pharmacolog pharmacokinet phase intraven IV pirarubicin patient good perform statu refractori tumor twenty-six minim prior therapi good risk extens prior therapi poor risk renal and/or hepat dysfunct total cours dose evalu maximum dose good-risk patient poor-risk patient dose-limit toxic effect transient noncumul granulocytopenia granulocyt nadir day rang frequent toxic effect thrombocytopenia anemia nausea mild alopecia phlebiti mucos myelosuppress patient hepat dysfunct pharmacokinet analys patient pirarubicin plasma alpha SE minut minut gamma hour area curv ng/ml hour volum distribut Vd total clearanc clt adriamycinol doxorubicin adriamycinon tetrahydropyranyladriamycinol metabolit plasma amount doxorubicin equal total metabolit urinari excret pirarubicin first hour equal activ mesothelioma leiomyosarcoma basal cell carcinoma recommend start dose phase II trial IV week